LUNDBECK PHARMACEUTICALS ITALY S.P.A.

LUNDBECK PHARMACEUTICALS ITALY S.P.A.

Company Introduction:

Lundbeck Pharmaceuticals Italy S.P.A. is the Italian subsidiary of H. Lundbeck A/S, a global pharmaceutical company headquartered in Denmark. Lundbeck is dedicated to improving the lives of people living with brain diseases by focusing on research, development, manufacturing, marketing, and sales of innovative treatments. While Lundbeck Pharmaceuticals Italy S.P.A. specifically manages the company's operations within Italy, Lundbeck's presence in India is primarily managed through its local operational entities or distribution partners, focusing on the sales, marketing, and distribution of its specialized pharmaceutical products to the Indian market.

Factory or Trader:

Lundbeck does not operate a manufacturing plant (factory) in India. Its operations in India are focused on the sales, marketing, and distribution of its pharmaceutical products, which are manufactured at its global production facilities outside of India. Therefore, in the context of India, Lundbeck functions as a sales and distribution organization for its own globally manufactured pharmaceutical products, rather than a local factory or a trader of third-party goods.

LUNDBECK PHARMACEUTICALS ITALY S.P.A., as part of the global H Lundbeck A/S group, sells or markets the following products in India:

Brintellix (Vortioxetine)

Rexulti (Brexpiprazole)

Ebixa (Memantine)

Azilect (Rasagiline)